50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Experimental GVHD and GVL

Tuesday, December 9, 2008: 7:00 AM-9:00 AM

3014-3016-3018 - West (Moscone Center)

Moderators:

Marcel R.M. van den Brink, MD, PhD and Bipin N. Savani, MD

7:00 AM

809

Preemptive HMG-CoA Reductase Inhibition Significantly Attenuates a Murine Chronic Graft-Versus-Host Disease

Ji-Young Lim^*, Hyung-Gyu Yoon^* and Chang-Ki Min^*

Department of Internal Medicine, St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea

7:15 AM

810

The Absence of CCR7 on Donor T Cells Leads to Attenuated Graft-Versus-Host Disease (GVHD) with a Preserved Graft-Versus-Leukemia (GVL) Effect

James M. Coghill, MD, Karen N. Hogan, BS^* and Jonathan S. Serody, MD, PhD^*

Lineberger Comprehensive Cancer Center, The University of North Carolina, Chapel Hill, NC

7:30 AM

811

Blockade of Interleukin 6 Signaling Attenuates Graft Versus Host Disease by Augmenting Regulatory T Cell Reconstitution

Xiao Chen, Ph.D.¹^*, Rupali Das, Ph.D.¹^*, Richard Komorowski, M.D.¹^*, Masahiko Mihara, Ph.D.²^* and William Drobyski, M.D.¹^*

¹Medical College of Wisconsin, Milwaukee, WI
²Chugai Pharmaceutical Co., Shizuoka, Japan

7:45 AM

812

Functional Comparison of Freshly Isolated and Ex-Vivo Expanded CD4⁺CD25⁺Foxp3⁺ Regulatory T Cells in Suppressing Murine Acute GvHD

Emanuela I Sega, PhD¹^*, Dennis Leveson-Gower, PhD¹^*, Vu H. Nguyen, MD² and Robert Negrin, MD³

¹Medicine/BMT, Stanford University, Stanford, CA
²Hematology/Oncology, University of Chicago, Chicago, IL
³Stanford University, Stanford, CA

8:00 AM

813

Generation of Treg-Like Cells from CD4+CD25- T Cells Occurs Via Both Foxp3 Dependent and Independent Pathways

Jaebok Choi, PhD¹^*, Julie Ritchey²^* and John F. DiPersio, MD, PhD¹

¹Internal Medicine, Washington Univ. in St. Louis, Saint Louis, MO
²Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, Saint Louis, MO

8:15 AM

814

SNP-Based Genome-Wide Identification of Hematopoiesis-Restricted Minor Histocompatibility Antigens

Pleun Hombrink, MSc¹^*, Sine R Hadrup, PhD²^*, Arne Bakker, PhD²^*, J.H. Frederik Falkenburg, Prof., MD, PhD¹, Peter A. Von Dem Borne, MD, PhD¹, Ton N Schumacher, Prof., PhD²^* and Mirjam H.M. Heemskerk, PhD¹

¹Hematology, Leiden Univ. Med. Ctr., Leiden, Netherlands
²Division of Imunology, Netherlands Cancer Institute, Amsterdam, Netherlands

8:30 AM

815

Novel Myeloma-Associated Antigens Revealed in the Context of Successful Syngeneic Hematopoietic Stem Cell Transplantation

Melinda A. Biernacki¹^*, Guanglan Zhang²^*, Wandi Zhang²^*, Vladimir Brusic, PhD²^*, Robert J. Soiffer, MD³, Donna Neuberg, ScD⁴, Edwin P. Alyea, MD³, Yu-Tzu Tai, PhD³, Nikhil C. Munshi, MD³, Jerome Ritz, MD³, Kenneth C. Anderson, MD³ and Catherine J. Wu, MD²

¹University of Connecticut School of Medicine, Farmington, CT
²Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA
³Department of Medical Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital/Harvard Medical School, Boston, MA
⁴Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

8:45 AM

816

Repression of NFAT1 Protein Expression by MicroRNA-184 in Umbilical Cord Blood-Derived CD4⁺ T-Cells as a Mechanism Underlying Lower Incidence of aGVHD

R. Patrick Weitzel¹^*, Mathew Lesniewski, PhD¹^*, Peter Haviernik, PhD¹^*, Laura Fanning¹^*, Marcie Finney¹^*, Patrick Leahy, PhD²^* and Mary J. Laughlin, MD³

¹Hematology/Oncology, Case Western Reserve University, Cleveland, OH
²Case Comprehensive Cancer Center, Cleveland, OH
³University Hospitals of Cleveland, Case Medical Center, Cleveland, OH

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

702.O2.8 Experimental GVHD and GVL